<DOC>
	<DOCNO>NCT01690624</DOCNO>
	<brief_summary>Patients acute myeloid leukemia experience relapse least one prior regimen may enrol trial . In addition , acute myeloid leukemia patient complete remission high risk relapse may eligible trial . The trial examine whether monotherapy BI 836858 safe tolerable escalate dose level .</brief_summary>
	<brief_title>BI 836858 Dose Escalation Patients With Refractory Relapsed Acute Myeloid Leukemia Patients Complete Remission With High Risk Relapse</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis relapse refractory AML least one prior treatment acute myeloid leukemia patient diagnosis acute myeloid leukemia complete remission high risk relapse . 2 . Expression CD33 30 % bone marrow blast screen patient refractory relapse acute myeloid leukemia require . CD33 positive expression bone marrow blast time initial acute myeloid leukemia diagnosis sufficient patient complete remission high risk relapse . 3 . Eastern Cooperative Oncology Group Performance Status 0 , 1 2 4 . Age 18 year old 5 . Written inform consent consistent International Conference Harmonization , Good Clinical Practice ( ICHGCP ) guideline local legislation . Exclusion criterion : 1 . Patients acute promyelocytic leukemia accord WHO definition . 2 . Patients refractory relapse acute myeloid leukemia &gt; 5.000 blast peripheral blood . 3 . Antileukemia therapy within two week first treatment BI 836858 , 4 week biologics . Parallel treatment Hydroxyurea ia allow refractory relapse acute myeloid leukemia patient . 4 . Allogeneic stem cell transplantation within last 28 day first treatment graft versus host disease require 20 mg steroid per day . Steroid dosage must stable within two week prior start treatment . 5 . Patients candidate allogeneic stem cell transplantation ( patient refractory relapse acute myeloid leukemia ) . 6 . Second malignancy currently require active therapy . 7 . Symptomatic central nervous system involvement 8 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( ULN ) , AST ALT great 5 time ULN Gilbert syndrome . 9 . Prothrombin time ( PT ) &gt; 1.5 x ULN subject therapeutic vitamin K antagonist ( phenprocoumon , warfarin ) 10 . Bilirubin great 1.5 mg/dl ( &gt; 26 Âµmol/L ) unless elevation thought due hepatic infiltration AML , Gilbert syndrome , hemolysis . 11 . Serum creatinine great 2.0 mg/dl 12 . Known human immunodeficiency virus ( HIV ) infection active hepatitis B virus hepatitis C virus infection . 13 . Concomitant intercurrent illness , condition opinion Investigator , would compromise safe participation study , e.g . active severe infection , unstable angina pectoris , new onset exacerbation cardiac arrhythmia 14 . Psychiatric illness social situation would limit compliance trial requirement 15 . Concomitant therapy , consider relevant evaluation efficacy safety trial drug 16 . Female patient childbearing potential sexually active unwilling use medically acceptable method contraception trial 6 month last administration BI 836858 17 . Male patient partner childbearing potential unwilling use condom combination second effective method contraception trial 6 month last administration BI 836858 18 . Pregnant nursing female patient 19 . Treatment another investigational agent follow condition : 1 . Within two week ( 4 week biologics 5 halflives , whichever long ) first administration BI 836858 ; 2 . Patient persistent toxicity prior antileukemic therapy determine relevant Investigator . 3 . Concomitant treatment another investigational agent participate trial . 20 . Prior treatment CD33 antibody 21 . Patient unable unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>